Drug Delivery
The European Commission approved Germany’s financial support after assessing the risks of Sanofi stopping insulin API production at the Frankfurt campus.
FEATURED STORIES
To successfully challenge Novartis on two planned fronts, Curium will need to overcome the unique challenges posed by radiopharmaceutical supply to get products to patients and win market share.
Blood centers have the donors, resources and community footprint drug sponsors need to solve supply chain issues around cell and gene therapies.
After mastering mass-market mRNA production during the pandemic, the industry now needs to achieve the timely delivery of individualized vaccines to thousands of patients.
Subscribe to Manufacturing Brief!
Weekly insight into the biggest trends in biopharma manufacturing
THE LATEST
With an internal non-opioid program nearing approval, Viatris is picking up Pacira BioSciences for a broader pain portfolio and the associated commercial infrastructure.
With the patent court siding with Halozyme, Merck faces restrictions on a product that won approval in Europe last year.
The investment will equip Bayer to make oncology, cardiovascular and renal care ingredients and drugs.
Despite the regulatory delay, Novo is still expecting a 2027 launch for its hemophilia A drug denecimig.
While AI is taking off in biopharma for administrative tasks and drug discovery efforts, more than 90% of drugmakers have yet to commit to scaling AI use in regulated biopharma manufacturing, according to CRB’s new Horizons: Life Sciences report.
After a series of clinical-stage failures, Alector is resetting around its preclinical blood-brain barrier delivery technology, securing a big pharma partnership along the way.
A surge of consolidation, rising appetite for specialized manufacturing and a shift toward decentralized trials is reshaping Switzerland’s life sciences landscape. From peptide producers to organoid CROs, service providers are scaling and diversifying as global sponsors turn to Swiss hubs for talent, innovation and regulatory strength.
Capitalizing on space’s microgravity, the United Therapeutics–partnered Varda Space Industries aims to make medicines with better bioavailability and stability than Earth-produced molecules.
Patients had adverse events after receiving a Fresenius Kabi medicine that experienced manufacturing deviations.
Time has run out on BioNTech’s bid to locate buyers for sites in Idar-Oberstein, Marburg and Tübingen. Including staff at a Singapore plant also slated for closure, the move could impact 1,860 jobs.